|
| |
Uveal NeoplasmsDownload PDF containing detailed information.
Recent Publications on Uveal Neoplasms: |  |
Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.
PURPOSE: To examine whether interferon (IFN)-alfa-2a treatment after... | 13th November, 2009
| Retina Service, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
| Ophthalmology. 2009 Nov;116(11):2206-12. Epub 2009 Sep 10.
DOI Direct Link |
To biopsy or not to biopsy?
PURPOSE: To examine whether interferon (IFN)-alfa-2a treatment after... | 11th November, 2009
|
| Acta Ophthalmol. 2009 Sep;87(6):586-7.
DOI Direct Link |
Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine.
BACKGROUND/AIMS: Liver is the most common site of metastases in uveal... | 30th October, 2009
| Department of Oncology and Radiotherapy, Palacky University Medical School
| Hepatogastroenterology. 2009 Jul-Aug;56(93):1157-62.
|
Irido-cilio-choroidal melanoma in a 5-year-old boy treated by Ru-106 brachytherapy.
The authors report a rare association of uveal effusion with presumed... | 29th October, 2009
|
| Clin Experiment Ophthalmol. 2009 Sep;37(7):742-3.
DOI Direct Link |
Uveal effusion simulating uveal ring melanoma.
The authors report a rare association of uveal effusion with presumed... | 23rd October, 2009
|
| Can J Ophthalmol. 2009 Oct;44(5):604-5.
DOI Direct Link |
→View more research publications. |
Press Releases About Uveal Neoplasms:
|
 |
| Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma |
7th May, 2009 |
Delcath Systems, Inc. |
NEW YORK, May 7 /PRNewswire-FirstCall/ -- Delcath Systems, Inc., (Nasdaq: DCTH) a medical technology company testing its proprietary Percutaneous Hepatic Perfusion (PHP(TM)) System for the treatment
|
| Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays |
4th May, 2009 |
Ipsogen SA |
MARSEILLE, France, May 4 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext
- FR0010626028 - ALIPS), a molecular diagnostic company specialized in the
development, the manufacturing and the
|
| New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkin's Lymphomas |
13th March, 2009 |
National Comprehensive Cancer Network |
NCCN presented new NCCN Clinical Practice Guidelines in Oncology(TM) for Primary Cutaneous B-Cell Lymphoma as well as important updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas at the
|
| Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting |
6th December, 2008 |
American Society of Hematology |
SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- Four studies highlighting late-breaking research advances in the treatment of cancer and sickle cell disease will be presented today at the 50th Annual
|
BioPortfolio Ltd. offers e-mail and postal lists for Uveal Neoplasms scientists - we have details of around 223 individuals working on Uveal Neoplasms .
This page has been viewed 326 times
Recent Search Terms used to find this page: uveal neoplasm | .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Uveal Neoplasms across BioPortfolio, or for Uveal Neoplasms Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
